{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:52:21Z","timestamp":1672843941237},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/maj.0b013e3181e939eb","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T09:31:57Z","timestamp":1281173517000},"page":"226-231","source":"Crossref","is-referenced-by-count":2,"title":["Pediatric Vaccines on the Horizon"],"prefix":"10.1016","volume":"340","author":[{"given":"Susana","family":"Ch\u00e1vez-Bueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence L.","family":"Stull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0010","first-page":"243","article-title":"Impact of vaccines universally recommended for children\u2014United States, 1990\u20131998","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.vaccine.2009.11.008","article-title":"Immunizing school-age children and adolescents: experience from low- and middle-income countries","volume":"28","author":"Mackroth","year":"2010","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0020","first-page":"1","article-title":"Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Murphy","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1086\/591966","article-title":"Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members","volume":"47","author":"Millar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0030","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMe068038","article-title":"Pneumococcal vaccine\u2014direct and indirect (\u201cherd\u201d) effects","volume":"354","author":"Musher","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2004.09.025","article-title":"Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children","volume":"23","author":"Piedra","year":"2005","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0040","first-page":"1","article-title":"Recommended immunization schedules for persons aged 0 through 18 years\u2014United States, 2010","volume":"58","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0045","first-page":"1","article-title":"Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","author":"National Center for Immunization and Respiratory Diseases","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0050","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","author":"Fiore","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0055","first-page":"1","article-title":"Quadrivalent Human Papillomavirus Vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/peds.2009-3194","article-title":"Policy statement\u2014recommended childhood and adolescent immunization schedules\u2014United States, 2010","volume":"125","author":"Committee on Infectious Diseases","year":"2010","journal-title":"Pediatrics"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0065","first-page":"921","article-title":"National, state, and local area vaccination coverage among children aged 19\u201335months\u2014United States, 2008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0070","first-page":"997","article-title":"National, state, and local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0075","first-page":"1","article-title":"Summary of notifiable diseases\u2013United States, 2007","volume":"56","author":"Hall-Baker","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00006454-199909000-00004","article-title":"Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers","volume":"18","author":"Shinefield","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0095","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(08)70281-0","article-title":"Impact of conjugate pneumococcal vaccines on antibiotic resistance","volume":"8","author":"Dagan","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3201\/eid0907.030083","article-title":"Disease surveillance and the academic, clinical, and public health communities","volume":"9","author":"Pinner","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","article-title":"Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine","volume":"295","author":"Poehling","year":"2006","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"4 suppl","key":"10.1097\/MAJ.0b013e3181e939eb_bb0120","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"4 suppl","key":"10.1097\/MAJ.0b013e3181e939eb_bb0125","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","article-title":"Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines","volume":"28","author":"Chevallier","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vaccine.2009.09.113","article-title":"Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age","volume":"28","author":"Prymula","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0140","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1016\/j.vaccine.2007.06.004","article-title":"Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults","volume":"25","author":"Scott","year":"2007","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1442-200X.2008.02593.x","article-title":"Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults","volume":"50","author":"Scott","year":"2008","journal-title":"Pediatr Int"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0150","series-title":"Antibody Responses to Routine Pediatric Vaccines When Administered with 13-Valent Pneumococcal Conjugate Vaccine. 47th Annual Meeting of the Infectious Diseases Society of America. Presentation Abstract 1195","author":"Bryant","year":"2009"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0155","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1016\/j.vaccine.2009.09.111","article-title":"Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease","volume":"27","author":"Hausdorff","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcl.2004.10.009","article-title":"Immunizations for the college student: a campus perspective of an outbreak and national and international considerations","volume":"52","author":"Kumar","year":"2005","journal-title":"Pediatr Clin North Am"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0175","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0180","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","author":"Rennels","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0185","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0200","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1016\/j.vaccine.2007.10.013","article-title":"A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants","volume":"25","author":"Nolan","year":"2007","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0b013e3181c3ce88","article-title":"Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants","volume":"29","author":"Marchant","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e3181cdd379","article-title":"Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (hibmency) at 12 to 15months of age","volume":"29","author":"Marshall","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"issue":"suppl 2","key":"10.1097\/MAJ.0b013e3181e939eb_bb0225","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0235","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"issue":"suppl 2","key":"10.1097\/MAJ.0b013e3181e939eb_bb0240","doi-asserted-by":"crossref","first-page":"B42","DOI":"10.1016\/j.vaccine.2009.05.001","article-title":"Meningococcal protein antigens and vaccines","volume":"27","author":"Feavers","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0245","series-title":"Immunogenicity and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6months of age","author":"Snape","year":"2008"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0250","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1086\/649210","article-title":"Conjugate meningococcal vaccines: lifesaving or inefficient use or both-no easy answer","volume":"50","author":"Pelton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.inf.0000148933.08301.02","article-title":"Six revolutions in vaccinology","volume":"24","author":"Plotkin","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0260","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1128\/CVI.00290-09","article-title":"Vaccines: the fourth century","volume":"16","author":"Plotkin","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1201.051043","article-title":"Making better influenza virus vaccines?","volume":"12","author":"Palese","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0270","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/CMR.00029-07","article-title":"Rotavirus vaccines: an overview","volume":"21","author":"Dennehy","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0275","doi-asserted-by":"crossref","first-page":"11626","DOI":"10.1128\/JVI.74.24.11626-11635.2000","article-title":"Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector","volume":"74","author":"Haller","year":"2000","journal-title":"J Virol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0280","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1128\/JVI.77.20.10819-10828.2003","article-title":"Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3\u2032 proximal genome positions of bovine\/human parainfluenza virus type 3 on virus replication and immunogenicity","volume":"77","author":"Tang","year":"2003","journal-title":"J Virol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0285","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/INF.0b013e318199c3b1","article-title":"Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children","volume":"28","author":"Gomez","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0290","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpeds.2007.07.015","article-title":"Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection","volume":"151","author":"Schleiss","year":"2007","journal-title":"J Pediatr"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0295","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1016\/j.vaccine.2006.02.031","article-title":"A review of vaccine research and development: the human immunodeficiency virus (HIV)","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0300","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.vaccine.2009.01.072","article-title":"Genome-based approaches to develop vaccines against bacterial pathogens","volume":"27","author":"Serruto","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0305","doi-asserted-by":"crossref","first-page":"13950","DOI":"10.1073\/pnas.0506758102","article-title":"Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial \u201cpan-genome\u201d","volume":"102","author":"Tettelin","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0310","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1126\/science.1109869","article-title":"Identification of a universal group B streptococcus vaccine by multiple genome screen","volume":"309","author":"Maione","year":"2005","journal-title":"Science"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0315","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1111563","article-title":"Genome analysis reveals pili in group B Streptococcus","volume":"309","author":"Lauer","year":"2005","journal-title":"Science"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0320","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/595564","article-title":"Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm","volume":"199","author":"Margarit","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0325","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/gb-2007-8-6-r103","article-title":"Characterization and modeling of the Haemophilus influenzae core and supragenomes based on the complete genomic sequences of Rd and 12 clinical nontypeable strains","volume":"8","author":"Hogg","year":"2007","journal-title":"Genome Biol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0330","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1128\/JB.00690-07","article-title":"Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: insights into the pneumococcal supragenome","volume":"189","author":"Hiller","year":"2007","journal-title":"J Bacteriol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0335","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI38330","article-title":"Vaccinology in the genome era","volume":"119","author":"Rinaudo","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0340","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Vaccines: correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0350","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0355","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","author":"Clark","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0360","doi-asserted-by":"crossref","first-page":"e7611","DOI":"10.1371\/journal.pone.0007611","article-title":"A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon","volume":"4","author":"Lell","year":"2009","journal-title":"PLoS One"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0365","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0031-3955(05)70214-5","article-title":"New combination vaccines","volume":"47","author":"Pichichero","year":"2000","journal-title":"Pediatr Clin North Am"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0370","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?","volume":"183","author":"Belyakov","year":"2009","journal-title":"J Immunol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0375","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tim.2009.12.001","article-title":"Potential role for mucosally active vaccines against pneumococcal pneumonia","volume":"18","author":"Jambo","year":"2010","journal-title":"Trends Microbiol"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0380","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/QCO.0b013e328332bbfe","article-title":"Group A streptococcal vaccines: facts versus fantasy","volume":"22","author":"Steer","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0385","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/S0264-410X(02)00205-0","article-title":"Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope","volume":"20","author":"Olive","year":"2002","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0390","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1016\/j.vaccine.2009.10.033","article-title":"Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study","volume":"27","author":"Arnou","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0395","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/649228","article-title":"Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles","volume":"201","author":"Kim","year":"2010","journal-title":"J Infect Dis"},{"issue":"suppl 6","key":"10.1097\/MAJ.0b013e3181e939eb_bb0400","doi-asserted-by":"crossref","first-page":"G60","DOI":"10.1016\/j.vaccine.2009.10.031","article-title":"Safety and immunogenicity of an influenza vaccine A\/H5N1 (A\/Vietnam\/1194\/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch","volume":"27","author":"Glenn","year":"2009","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0405","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2009.11.007","article-title":"The expanding vaccine development pipeline, 1995\u20132008","volume":"28","author":"Davis","year":"2010","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0410","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1377\/hlthaff.24.3.622","article-title":"Why are pharmaceutical companies gradually abandoning vaccines?","volume":"24","author":"Offit","year":"2005","journal-title":"Health Aff (Millwood)"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0415","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.vaccine.2009.09.047","article-title":"Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles","volume":"28","author":"Lee","year":"2010","journal-title":"Vaccine"},{"key":"10.1097\/MAJ.0b013e3181e939eb_bb0420","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1542\/peds.2008-2038","article-title":"Variation in provider vaccine purchase prices and payer reimbursement","volume":"122","author":"Freed","year":"2008","journal-title":"Pediatrics"},{"issue":"suppl 5","key":"10.1097\/MAJ.0b013e3181e939eb_bb0425","doi-asserted-by":"crossref","first-page":"S558","DOI":"10.1542\/peds.2009-1542P","article-title":"Financing vaccination of children and adolescents: National Vaccine Advisory Committee recommendations","volume":"124","author":"National Vaccine Advisory Committee","year":"2009","journal-title":"Pediatrics"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915315020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:23:59Z","timestamp":1559391839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915315020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0002962915315020"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181e939eb","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}